Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

OCTOBER 9, 2021

Data from the Denver District Attorney’s office shows only 47 cases related to psychedelic mushrooms since May 2019 decriminalization. The panel that includes District Attorney Beth McCann, law enforcement officers and psilocybin advocate Kevin Matthews was formed after 2019, when Denver voters were the first in the U.S.

Decriminalization 52

Decriminalization Law Data Safety 52

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz and colleagues have published a paper summarizing ORR data from individuals with epilepsy in the medical journal Epilepsy & Behavior. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

NORML

MARCH 23, 2020

The National Organization for the Reform of Marijuana Laws wishes to reiterate its message that cannabis consumers and others beware of online misinformation surrounding the use of either whole-plant cannabis or CBD as a potential remedy for the COVID-19 virus.

CBD 342

CBD Therapy Treatment Packaging 342

The Cannigma

NOVEMBER 23, 2021

The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects. We delve into how data can further our understanding of different types of cannabis and why standardization is desperately needed in the industry.

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

JANUARY 9, 2019

“I would never have thought to get into the medical cannabis industry, it always just seemed like an excuse for people to get high,” he told Cannabis Law Report. Then I saw someone with Stage 4 breast cancer end up in remission from cannabis-based therapy, someone else with skin cancer; kid after kid with seizures all being treated.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Cannabis Law Report

SEPTEMBER 28, 2021

The data will then be analysed to recognise trends in responses. • Participants: The survey is open to all ACT residents over 18 years. • Use of Data and Feedback: The data will be used in my ANIP thesis and possibly for future research. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data.

Therapy 52

Therapy Medicine Data Collective 52

Cannabis Law Report

DECEMBER 8, 2021

Access to headline, upfront, milestone and royalty data. Specific therapy indication. Which jurisdiction does the company insist upon for agreement law? Access Psychiatry deal headline, upfront, milestone and royalty data. Advanced Cooling Therapy. Analysis of Psychiatry deal structure. Upfront payment value.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

APRIL 21, 2021

A new tool provides speed to market with novel psychedelic therapies through deeper data analytics.… … Read More.

Therapy 98

Therapy Data 98

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. the laws surrounding the substance can be a little confusing.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Canna Law Blog

NOVEMBER 10, 2021

Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “ breathtaking ” in the words of Compass’ CEO. First, the trial data contained some problematic features, which I’ll address below.

Therapy 87

Therapy Data Clinical Trials Treatment 87

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. IGC), based in Maryland, engages in developing cannabinoid-based therapies for healthcare applications.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. Cancer therapy targets the cells that are dividing uncontrollably, while avoiding damage to the non-cancerous cells. How do we currently treat cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

JULY 16, 2021

The diversified venture fund said in a statement that it is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Wesana Health Holdings Inc. CSE: WESA) (OTC: DBDIF) is buying Psychedelitech Inc.,

Therapy 124

Therapy Data Patients 124

Cannabis Law Report

FEBRUARY 14, 2020

Consumer products law blog. Class actions against CBD companies proliferate under federal and state law. Product testing and sampling protocols are not uniform across the country, and scientific data supporting the safety and efficacy of these products is under-developed. Plaintiffs claim damages in excess of $5 million.

State Laws 59

State Laws Law CBD Food 59

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. An abundance of science and public health data supports it. A Q&A with Mason Marks on new psychedelics law and regulation initiative. Want more of what he thinks?

Research and Development 52

Research and Development Therapy Access Data 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. IGC) engages in the development of cannabinoid-based therapies for healthcare applications. million individuals in the U.S.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Watch how Supera-CBD works. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States.

Law 52

Law Programs Therapy Education 52

Veriheal

JULY 18, 2023

This could foster a pool of experts well-versed in applying psychedelic-assisted therapy. This will ensure that lawmakers stay informed about the program’s developments and can respond accordingly as new data emerges. Supporters range from Rep.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

JULY 22, 2021

As regulations develop, the next phase of the Company’s strategy will involve the inclusion of alternative and psychedelic therapies into Levitee’s platform of traditional healthcare assets. This news release contains certain statements that may constitute forward-looking information under applicable securities laws.

eCommerce 105

eCommerce Therapy Media Access 105

Veriheal

JUNE 19, 2023

All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. The report highlighted that “changes associated with psychedelic drug laws and policies are complicated and are resulting in changeable forms of application across different geographical areas.”

Therapy 109

Therapy Treatment Patients Policy 109

MMJ Recs

NOVEMBER 17, 2023

Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. Research and Innovation: Maryland’s MMJ program encourages research and innovation in the field of cannabis-based therapies, benefiting patients both in the state and nationwide.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

AUGUST 5, 2019

Ojai Energetics initiated and co-sponsored the legislation signed by Governor Jerry Brown of California that pushed hemp legislation SB 1409 into law, a move that significantly expanded hemp farming in California. Read more. . USA Today Report: Cannabis Consumers Reduce Use of Pills, Booze. . Read more. . More Kroger Co.

Law 40

Law Decriminalization Hemp Legislation 40

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

SEPTEMBER 12, 2021

The bill’s sponsor, State Assemblyman Steve Yeager, introduced the measure in February because Nevada law was unclear about whether veterinarians were permitted to administer CBD products or discuss them with pet owners. THC, despite laws in many states permitting it under various circumstances, is illegal under federal law.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

NOVEMBER 11, 2021

The Panel included representatives of law enforcement, the Denver District Attorney’s Office, harm reduction experts, licensed therapists, and proponents of the original measure. The City should create a data collection reporting system for any interactions involving psilocybin for ongoing public safety monitoring. Source: [link].

Policy 52

Policy Decriminalization Safety Therapy 52

The Cannigma

AUGUST 5, 2022

But today, thanks to a combination of changing laws and attitudes and a building consensus of scientific research, there’s another, perhaps unexpected option – ketamine. 2 In 2019 the FDA approved a keta m ine-based nasal spray to treat depression that does not respond to other therapies. What is ketamine treatment?

Treatment 138

Treatment Research and Development Therapy Digestion 138

Cannabis Law Report

MAY 26, 2022

Successful Behavioral Addiction Study Supplied Data for Patent. The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. Awakn Life Sciences Corp. ( Awakn Life Sciences Corp. (

Treatment 52

Treatment Research and Development Therapy Data 52

Cannabis Law Report

SEPTEMBER 23, 2021

This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program. Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (drugs and therapies to be used in combination) to better treat addiction.

Research and Development 52

Research and Development Therapy Treatment Data 52